You went to a doctor. They told you testosterone therapy wasn't right for you — maybe because you're in your 30s, maybe because of your prostate history, maybe because your lab numbers weren't in the right box on the wrong checklist.

On June 18, 2026, HHS asked the FDA to update the class-wide labeling for testosterone replacement therapy. If those changes are finalized, some of the reasons you were told you don't qualify may no longer be on the label.

Here is what actually changed — and what it means for men who want a real conversation with a real provider.

What the FDA Label Update Proposed

HHS submitted a formal request to the FDA to revise labeling across the testosterone therapy drug class. Three changes are at the center of the proposal:

1. Remove the "age-related hypogonadism" restriction. Current labeling tells prescribers the drug is "not established" for men with low testosterone due to aging alone. The proposed update would remove that language — opening the door for providers to have a more individualized conversation with older patients whose testosterone is declining.

2. Narrow the prostate cancer contraindication. The current label broadly warns against testosterone therapy in men with prostate cancer. The proposed revision would narrow that to metastatic prostate cancer only — distinguishing between men with a history of localized prostate cancer (who may not have meaningful contraindication) and those with active, advanced disease.

3. Revise BPH warnings. The update would also revise how the label characterizes risk for men with benign prostatic hyperplasia. Specific revisions are still under FDA review.

These are proposed label changes submitted by HHS. They are not final. Prescribing decisions remain with your provider, not the label.

What Drove the Proposal: The TRAVERSE Trial

The TRAVERSE trial was a randomized, placebo-controlled trial of more than 5,200 men with low testosterone and pre-existing or high cardiovascular risk. Published in the New England Journal of Medicine in 2023, it was designed to test one specific question: whether testosterone therapy increased the rate of major adverse cardiac events (heart attack, stroke, or cardiovascular death) compared to placebo. It did not — testosterone met the pre-defined bar for non-inferiority on that endpoint. That is a narrower finding than "testosterone is safe for the heart," and it is worth being precise about what the trial did and did not show.

TRAVERSE did not stand alone. The FDA had required a cardiovascular safety trial after adding a class-wide CV warning in 2015, because earlier observational studies and smaller trials had produced mixed and inconclusive signals — some suggesting harm, others none. Later meta-analyses of prior randomized trials also failed to find a clear increase in major cardiac events. TRAVERSE was the large, purpose-built trial the field had been waiting for, and its result was consistent with that broader body of evidence rather than a lone data point.

That combined picture matters because the existing testosterone label carries a cardiovascular risk warning — a warning that has shaped how providers think about who qualifies for TRT for years. The TRAVERSE data, read alongside the prior evidence, gave HHS and the FDA a research foundation to revisit those restrictions. It did not establish that testosterone is safe for every patient, and TRAVERSE itself flagged secondary safety signals worth watching.

What the trial still flagged: A "no increase in major cardiac events" result is not the same as "no cardiovascular effects." TRAVERSE itself reported higher rates of some secondary events in the testosterone group — including atrial fibrillation and pulmonary embolism — and, together with associated ABPM studies, a modest blood pressure increase in some men. That is exactly why the proposed labeling revisions include a blood pressure monitoring requirement. If you are considering TRT, ongoing BP and symptom monitoring is part of a supervised protocol — not a footnote. Any provider worth working with will track this.

What This Means If You've Been Told You Don't Qualify

The label is not law. It is guidance. Providers have always had clinical discretion.

But the label matters — it shapes what most physicians feel comfortable prescribing, how insurance companies cover it, and what most online providers will offer. When the label says "not established for age-related hypogonadism," many providers read that as a hard stop.

If the proposed changes are finalized, those providers will have new ground to stand on. That means:

None of this is a green light. It is a signal that the science has evolved and the label is catching up.

Why Supervised Care Matters More, Not Less

Here is the thing about the label changing: it makes getting TRT easier to access through direct-to-consumer channels. That is mostly good news — but it also means the quality gap between providers widens.

Anyone can read an updated label. Not every provider will dig into your history, track your labs, monitor your blood pressure, and adjust your protocol over time.

The TRAVERSE trial's population was carefully selected, closely monitored, and protocol-defined. That kind of rigor does not transfer automatically to a provider who sends you a questionnaire and a vial and calls it done.

Supervised TRT — with ongoing labs, provider check-ins, and dosing that adjusts to how your body responds — is what the research was actually testing. That is what a quality protocol looks like.

What Happens Next

As of publish date, the proposed label changes are under FDA review. There is no announced timeline for finalization. The FDA may accept the HHS proposal as submitted, request modifications, or open a formal comment period.

Follow the FDA's drug-labeling announcements for updates. Your provider — not a news cycle — is the right source for guidance on how this affects your specific situation.

If you have been told you don't qualify for TRT and want to understand your options, start with a licensed provider who will actually review your labs, your history, and the evolving evidence. That conversation is what Nuvari is built around.

Nuvari does not dispense testosterone. For men's hormone health it offers a different route: the Apex Protocol page for compounded enclomiphene explains what the medication is, how it compares to TRT, and the men it is not appropriate for — including primary hypogonadism, liver disease, and a history of venous thromboembolism.

Explore supervised wellness protocols.

FAQ Section

What did HHS propose to change about testosterone therapy labeling in 2026?

On June 18, 2026, HHS asked the FDA to revise class-wide labeling for testosterone replacement therapy. The proposed changes include removing the "not established for age-related hypogonadism" restriction, narrowing the prostate cancer contraindication to metastatic-only cases, and revising BPH warnings. These are proposed changes — not finalized label updates.

Does the FDA label change mean I now qualify for TRT?

Not automatically. Proposed label changes remove some of the explicit label-based restrictions, but prescribing decisions remain with your provider. Your individual health history, labs, and risk factors all factor into that decision. The proposed changes create more room for a nuanced clinical conversation — they are not a blanket approval for anyone who asks.

What is the TRAVERSE trial and why does it matter for TRT?

The TRAVERSE trial was a randomized, placebo-controlled trial of more than 5,200 men with low testosterone and elevated cardiovascular risk, published in the New England Journal of Medicine in 2023. It was designed to test whether testosterone therapy increased major adverse cardiac events (heart attack, stroke, or cardiovascular death) versus placebo, and it met the pre-defined bar for non-inferiority on that endpoint — meaning it did not show an increase in those events. That is a specific finding, not a blanket statement that TRT is safe for the heart: the trial also flagged secondary signals such as atrial fibrillation, pulmonary embolism, and a modest blood pressure increase in some men. Read alongside earlier trials and meta-analyses, the TRAVERSE data provided a research basis for revisiting existing cardiovascular risk warnings on testosterone labels.

Is testosterone therapy safe if I have prostate cancer?

That depends on the type and stage. The proposed label revision would narrow the prostate cancer contraindication from a broad warning to a restriction specific to metastatic prostate cancer. Men with a history of localized prostate cancer may find a different clinical conversation available to them if the changes are finalized — but this is a decision to make with a urologist or specialist, not based on a label change alone.

If the FDA finalizes the label changes, does anything happen automatically?

No. A finalized label update changes what prescribers have documented guidance on — it does not automatically change what any specific provider, insurance company, or telehealth platform offers. Adoption varies. The right move is to talk to a licensed provider who stays current on the evidence and evaluates your individual situation — which is exactly the kind of clinician Nuvari connects you with. Take the free assessment.